| abstract |
FIELD: medicine. n SUBSTANCE: invention relates to medicine, transplantation, cardiac surgery and cardiac intensive care, and can be used to increase the possibilities of hart transplantation and prevention of the development of severe post-transplant right ventricular heart failure in patients with initially high vascular resistance of the pulmonary circulation. For this purpose, recipients are given intravenous infusion of Levosimendan at a dose of 12.5 mg at a rate of introduction of 0.05–0.2 mcg/kg/min for 24–40 hours, with continuous invasive monitoring of blood circulation and maintaining the level of mean arterial pressure not lower than 65 mm Hg; 72 hours after the end of the infusion of Levosimendan, pulmonary artery catheterization is repeated, the hemodynamic parameters are measured and the PVR is calculated, the PVR data obtained before and after the infusion of Levosimendan are analyzed, and a conclusion is made about the possibility of performing a heart transplant. n EFFECT: method allows to reduce pulmonary vascular resistance, reduce the risk of developing severe RVHF in the postoperative period and reduce the number of failures in heart transplantation in patients with severe CHF. n 1 cl |